

# Financial Tear Sheet

## Corporate Profile

- We are a biotechnology company pioneering a unique set of therapeutic and drug profiling capabilities based on our revolutionary ability to 3D bioprint tissues that mimic human biology and disease.
- We are developing in vivo liver tissues to treat a range of rare, life-threatening diseases, for which there are few current treatment options other than organ transplantation.
- We are harnessing our foundational ability to characterize specialized human cells and to 3D bioprint functional tissues to create novel in vitro toxicology and liver disease modeling platforms.
- We are striving to change the face of medicine through clinical development of regenerative medicine therapies for treating disease and by enabling translational drug discovery.

## Primary IR Contact

Steve E. Kunszabo  
 VP, Investor Relations &  
 Corporate  
 Communications  
**Phone:** 858-224-1092  
**Email:**  
 skunszabo@organovo.com

## Stock Information

| ONVO (Common Stock)              |                       |
|----------------------------------|-----------------------|
| Exchange                         | NASDAQ (US Dollar)    |
| Price                            | <b>\$1.13</b>         |
| Change (%)                       | <b>▲ 0.06 (5.61%)</b> |
| Volume                           | 1,327,915             |
| 52 Week Low                      | \$0.90                |
| Market Cap                       | \$127,857,875         |
| Rolling EPS                      | -0.24                 |
| PE Ratio                         | 0                     |
| Shares Outstanding               | 119,493,341           |
| Data as of 02/22/19 4:00 p.m. ET |                       |



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Recent Press Releases & Upcoming Events

02/20/19

Organovo Appoints New Board Member

02/07/19

Organovo Affirms Key Clinical Development Goals;  
Company Reports Fiscal Third-Quarter 2019  
Results

01/17/19

Organovo Announces Release Date for Fiscal Third-  
Quarter 2019 Financial Results

There are currently no events scheduled.

## SEC Filings

| Filing Date | Form |
|-------------|------|
| 02/21/19    | 4    |
| 02/21/19    | 4    |
| 02/21/19    | 4    |
| 02/21/19    | 4    |

## Corporate Governance

|                                |  |
|--------------------------------|--|
| Taylor J. Crouch               | President & Chief Executive Officer  |
| Sharon Collins Presnell, Ph.D. | Chief Scientific Officer, Organovo & President, Samsara                        |
| Eric Michael David, M.D., J.D. | Chief Strategy Officer and Executive Vice President of Preclinical Development |
| Jennifer Kinsbruner Bush, J.D. | General Counsel, Corporate Secretary and Compliance Officer                    |
| Susan Daugherty                | Senior Vice President, Human Resources   |
| Paul Gallant                   | General Manager  |